<DOC>
	<DOCNO>NCT02434276</DOCNO>
	<brief_summary>This multi-center , randomize , double-blind , active comparator control study 450 healthy adult age 18-64 year administer either one two dose level VAX2012Q license quadrivalent influenza vaccine . The subject randomize 1:1:1 ratio .</brief_summary>
	<brief_title>Study Immunogenicity Safety Quadrivalent Influenza Vaccine ( VAX2012Q ) Adults 18-64 Years</brief_title>
	<detailed_description>This multi-center , randomize , double-blind , active comparator control study 450 healthy adult age 18-64 year administer either VAX2012Q Fluzone . Four hundred fifty ( 450 ) subject randomize 1:1:1 ratio either 8 12 mcg VAX2012Q dose level Fluzone® Quadrivalent vaccine . Randomization stratify age ( 18-49 50-64 year ) . Subjects stratify two age group ( 18-49 50-64 ) randomize 1:1:1 ratio either 8 12 mcg VAX2012Q dose level Fluzone® Quadrivalent vaccine . 25-35 % total study population recruit 50-64 age group . The primary objective study evaluate seroconversion rate Day 21 dose level VAX2012Q .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Hemagglutinins</mesh_term>
	<criteria>Males female , 1864 year age . Females must : 1 . Surgically sterilize 2 . Post menopausal : 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum folliclestimulating hormone ( FSH ) level &gt; 40 milliInternational Units ( mIU ) /ml 6 week postsurgical bilateral oophorectomy 3 . Those childbearing potential must negative pretreatment serum pregnancy test follow confirmatory urine pregnancy test immediately prior vaccination must agree use reliable form contraception least 21 day post vaccination include contraceptive , intrauterine device , doublebarrier method . In good health determine medical history , physical exam , laboratory assessment clinical judgment Principal Investigator . Must sign inform consent indicate understand purpose procedure require study willingness participate . Within 6 month precede administration study vaccine , receive licensed investigational vaccine . Within 30 day precede administration study vaccine , receive investigational drug . Excessive chronic alcohol use within last 5 year . History drug abuse , recreational cannabis use , within last 5 year could affect subject 's participation study . Significant psychiatric illness within last 12 month would interfere study . A chronic illness medically stable , receive concomitant therapy medication dose stable least 3 month prior immunization condition could interfere study . Clinically significant abnormal liver function test screen : alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 Upper Limit Normal ( ULN ) . Total bilirubin &gt; 1.5 ULN ALT AST &gt; ULN total bilirubin &gt; 2 ULN ALT AST within normal range . Creatinine &gt; 1.7mg/dL , Hemoglobin &lt; 11g/dL female ; &lt; 12.5 g/dL male , white blood cell ( WBC ) &lt; 2500cell/mm3 &gt; 15,000cell/mm3 , Platelet Count &lt; 125,000cell/mm3 Positive serology HBSAg , hepatitis C virus ( HCV ) HIV Have cancer receive treatment cancer within three year , exclude situ cervical carcinoma basal /squamous cell carcinoma skin vaccination site . Any autoimmune disease . Presently receive recent history receiving ( ≤ six month ) medication therapeutic modality affect immune system drug know frequently associate significant major organ toxicity system corticosteroid ( oral injectable ) . History severe allergic reaction previous vaccination hypersensitivity seasonal influenza vaccine component . Allergic egg egg product . History GuillainBarré Syndrome . Receipt blood blood product 8 week prior vaccination plan administration three week study period follow vaccination Donation blood blood product within 4 week prior vaccination 4 week study period follow vaccination . Acute disease within 72 hour prior vaccination . An oral temperature &gt; 100.4°F ( 38°C ) day vaccination Body Mass Index &gt; 40 . Known bleed disorder receive prescribed oral parenteral anticoagulant . Any condition circumstance , opinion Principal Investigator , pose unacceptable risk participation study could interfere study evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>